000			03812nam a22003975c 4500
001			76066
003			ES-MaUEC
005			20230207040207.0
007			cr nn 008mamaa
008			130913s2013 xxu| s |||| 0|eng d
020			_a9781461488699
024	7		_a10.1007/978-1-4614-8869-9 _2doi
040			_aES-MaUEC
050		4	_aRA644.L25 _bK86 2013 EB
082	0	4	_a616.079
100	1		_aKumar, Awanish _984916 _0Local
245	1	0	_aLeishmania and Leishmaniasis _cby Awanish Kumar
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (XI, 83 p.) _b14 ilustraciones, 11 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aSpringerBriefs in Immunology _x2194-2773 _v3
505	0		_aHistorical background of Leishmania and leishmaniasis -- Risk factors and definition of the problem -- Types of leishmaniasis -- Global status of visceral leishmaniasis -- Status of visceral leishmaniasis in India -- Morphology and Life cycle of Leishmania donovani -- Vectors and transmission of the disease -- Clinical symptoms of visceral leishmaniasis -- Control strategies of the disease -- Leishmania/HIV co-infections -- Host Immune response to Leishmania infection -- Cross-immunity between different Leishmania species -- Adoptive transfer of immunity -- Cutaneous leishmaniasis -- Mucocutaneous Leishmaniasis -- Visceral Leishmaniasis -- Post Kala-azar dermal Leishmaniasis -- Drugs against leishmaniasis -- Antimonials and Leishmaniasis -- SAG treatment, failure and resistance in Leishmania -- Vaccines against Leishmaniasis -- Strategy in practice for vaccine development against Leishmanisis
520			_aLeishmania-related illnesses remain among the world{u2019}s deadliest neglected tropical diseases, affecting approximately 12 million people in 88 countries.The mortality rate is substantial, contributing to nearly two million disability-adjusted life years. As more is understood about this parasite and its effects, work toward prevention, control, and treatment continues apace.Leishmania and Leishmaniasis will address the parasite and its attendant disease, which manifests in three syndromes: Visceral (VL), Cutaneous (CL) and Mucocutaneous Leishmaniasis (ML). The morphology and life cycles of the various species will be among the topics addressed in Part One. Part Two will focus on immunology, including host-immune response to Leishmania infection, cross-immunity between the different species and adoptive transfer of immunity. Parts Three and Four will address how Leishmania invade and survive, the clinical features of the disease, and its diagnosis.Drugs, vaccines and treatment will be thoroughly explored, including experimental models of therapeutics. Leishmania and Leishmaniasis will provide a thorough examination of a parasite, the illnesses it causes and the misery it continues to visit upon large segments of the population
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisado
650		7	_aLeishmaniosis cutánea _9167550 _0comprobar BNE20070130004 _2embne
650		7	_aEnfermedades por protozoos _9166371 _0comprobar BNE20061375848 _2embne
650		7	_aEnfermedades infecciosas _0comprobar BNE19900959429 _2embne _9138404
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-8869-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781461488699
907			_a.b1281684x _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b11-05-17 _cm _dz _eb _feng _gxxu _h0
945			_aRA644 .L25 K86 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11546062 _z06-04-17
999			_c76066 _d76066 _x1